Core Insights - Astrana Health, Inc. reported record financial results for the year ended December 31, 2025, with total revenue of $3,181.8 million, a 56% increase year-over-year, and adjusted EBITDA of $205.4 million, up 21% from the previous year [1][2][5] - The company anticipates approximately 24% revenue growth and 29% adjusted EBITDA growth for 2026, driven by the integration of Prospect Health [1][2] Financial Highlights for Year Ended December 31, 2025 - Adjusted EPS - diluted of $2.20 [1] - Adjusted EBITDA of $205.4 million, up from $170.4 million [1] - Total revenue of $3,181.8 million, up from $2,034.5 million [1] - Net income attributable to Astrana of $22.5 million [1] Financial Highlights for Fourth Quarter 2025 - Total revenue of $950.5 million, a 43% increase from $665.2 million [1] - Adjusted EBITDA of $52.5 million, up 50% from $35.0 million [1] - Net income attributable to Astrana of $6.0 million [1] Segment Results for Year Ended December 31, 2025 - Care Partners revenue of $3,022.6 million, up 55% from $1,949.0 million [1] - Care Delivery revenue of $250.7 million, up 83% [2] - Care Enablement revenue of $246.7 million, up 59% [2] Update on Annual Report Filing - The company plans to file a Form 12b-25 to extend the deadline for its Annual Report on Form 10-K due to a material weakness in internal control over financial reporting [1][2] Stock Repurchase Program - The Board of Directors increased the share repurchase program from $50 million to $100 million, with $35.9 million remaining available as of December 31, 2025 [1][2] 2026 Guidance - For the three months ending March 31, 2026, total revenue is expected to be between $900 million and $1,000 million, and adjusted EBITDA between $60 million and $70 million [2][5] - For the year ending December 31, 2026, total revenue guidance is between $3,800 million and $4,100 million, and adjusted EBITDA between $250 million and $280 million [2][5]

results to differ materially from those in the forward-looking statements include (1) the timing and extent of changes in raw material and component prices, (2) the effects of fluctuations in the commercial/industrial new construction market, (3) the timing and extent of changes in interest rates, as well as other competitive factors during the year, and (4) general economic, market or business conditions. For a discussion of such risks and uncertainties, which could cause actual results to differ from thos ...

Prepares for fully funded, 5,000 m drill program, testing new targets WHITE ROCK, BC / ACCESS Newswire / March 2, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce the receipt of permits (PR 25 00201) for its upcoming maiden drill program at its flagship Laird Lake project, located in Ontario's world-class Red Lake Gold District. With receipts in hand, drill contractors selected, and targets further refined (including new geophysical interpretations), ...

Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors [Accessibility Statement] Skip NavigationGRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26 ...

igsh=MW9jY3g0MmZiaG5pNg%3D%3D&utm_source=qr#]Follow us on YouTube: [https://www.youtube.com/@GreenRainEnergy]Forward Looking Statements:This release contains forward- looking statements under Sections 27A and 21E of U.S. securities laws, subject to safe harbor provisions. These statements involve risks and uncertainties that could cause actual results to differ materially, including technical, permitting, or other challenges. Green Rain Energy assumes no obligation to update forward-looking statements excep ...

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026 Maintained strong cash position with approximately $310.3 million in cash and cash equivalents, exp ...

Thomson Reuters Announces Planned CFO Transition [Accessibility Statement] Skip NavigationTORONTO, March 2, 2026 /PRNewswire/ -- Thomson Reuters (TSX/Nasdaq: TRI), a global content and technology company, today announced that Mike Eastwood, Chief Financial Officer, will retire from the role following a planned transition. Mr. Eastwood will become Chairman of the Board of the Thomson Reuters Foundation, succeeding Jim Smith, who previously served as President and CEO of Thomson Reuters. Mr. Eastwood will als ...

HOLON, ISRAEL, March 2, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results for the fourth quarter and full year 2025 and provided a corporate update. Dr. Ophir continued, "Across our pipeline, we continue to execute with discipline. In 2025, we initiated dosing in new clinical trials of COM701 MAIA-ovarian and of GS-0321 Phase 1 and expanded our clinica ...

Criteo Joins OpenAI Advertising Pilot in ChatGPT [Accessibility Statement] Skip NavigationThe integration enables brands to leverage Criteo's digital advertising platform as part of OpenAI's ad pilotNEW YORK, March 2, 2026 /PRNewswire/ -- [Criteo](NASDAQ: CRTO), the global platform connecting the commerce ecosystem, today announced it is the first advertising technology partner integrating with OpenAI's [advertising] [pilot] [in ChatGPT] Free and Go versions in the United States."This integration with OpenA ...

Core Viewpoint - The Justice Department is initiating a trial to potentially force the breakup of Live Nation and Ticketmaster, indicating significant regulatory scrutiny in the live entertainment industry [1] Group 1: Legal and Regulatory Actions - The trial is set to begin on Monday, highlighting the urgency and importance of the case in the context of antitrust concerns [1] Group 2: Industry Implications - The potential breakup of Live Nation and Ticketmaster could reshape the landscape of the live entertainment and ticketing industry, affecting competition and market dynamics [1]